Eylea (aflibercept 2 mg) — HCPCS J0178

Eylea vs. Eylea HD — J0178 vs. J0177 FDA verified May 2026

Same molecule, two formulations, two J-codes. Pre-claim verification matters.

Regeneron's aflibercept comes in two FDA-approved formulations: the original Eylea (2 mg), approved November 2011 (BLA 125387), billed under HCPCS J0178; and Eylea HD (8 mg high-dose), approved August 2023, billed under HCPCS J0177. They are not interchangeable for billing — every code, NDC, and unit count differs. ROP (retinopathy of prematurity) is approved for Eylea 2 mg only and is NOT an Eylea HD indication.

This page covers reference Eylea (J0178). The Eylea HD (J0177) reference page covers the high-dose formulation. Aflibercept biosimilars are summarized in the next section.

The 6 aflibercept biosimilars — Q-codes, interchangeability, ASP CMS HCPCS + FDA verified May 2026

Six FDA-approved biosimilars now reference Eylea 2 mg. Two are designated interchangeable. None reference Eylea HD.

As of May 2026, the FDA has approved six aflibercept biosimilars referencing reference Eylea (J0178). Each biosimilar carries its own Q-code on the claim — you cannot bill a biosimilar under J0178. Two biosimilars (Yesafili and Opuviz) carry the FDA interchangeable designation, meaning a pharmacist may substitute them for reference Eylea without prescriber approval where state law allows. The other four are biosimilars but not interchangeable; substitution requires prescriber approval.

Pavblu (Q5147) Q2 2026 ASP snapshot

Pavblu (Amgen, Q5147) was the first non-interchangeable aflibercept biosimilar to gain a permanent Medicare code (effective April 1, 2025). Its Q2 2026 ASP+6% sits at $821.396/mg, which makes a 2 mg dose of Pavblu approximately $1,642.79. Other biosimilars are still in early launch and may not yet appear on every quarterly ASP file; check the current CMS Part B Drug ASP Pricing File before quoting.

Eylea HD biosimilars: none

All six approved aflibercept biosimilars reference the original Eylea 2 mg formulation only. There are no biosimilars of Eylea HD (J0177) as of May 2026. Payers seeking lower-cost ophthalmic anti-VEGF alternatives to Eylea HD have only repackaged off-label bevacizumab (Avastin) as a step-therapy option.

Dosing per indication FDA label verified May 2026

From FDA prescribing information (BLA 125387). Five indications including pediatric ROP.

Pediatric (non-ROP)

Outside of ROP, the FDA label states pediatric safety and effectiveness for wAMD, RVO, DME, and DR are not established. Off-label pediatric use will face payer authorization scrutiny.

NDC reference FDA NDC Directory verified May 2026

Vial vs. PFS: Regeneron offers the 2 mg dose as both a single-use vial and a prefilled syringe. The active drug, dose, and J-code are identical — only the NDC differs (last segment 02 vs. 01). Confirm the NDC matches the actual presentation administered. Some payers prefer one configuration; ASC/site contracts may dictate which is purchased.

CPT 67028 & bilateral rules CPT verified May 2026

Intravitreal injections have unique laterality rules — per-eye billing, RT/LT preferred over modifier 50.

Bilateral same-day injections — RT/LT, not modifier 50

For bilateral Eylea injections on the same date of service, most payers require two separate line items:

• Line 1: 67028-RT, 1 unit, full fee
• Line 2: 67028-LT, 1 unit, full fee

Some commercial payers accept the alternative single-line format with modifier 50:

• 67028-50, 1 unit, fee doubled

Per AAPC: "It is important to check with individual payers as some may require the procedure to be billed on two separate lines with -RT and -LT modifiers instead of using -50." Modifier 50 is not preferred for retina; RT/LT is the safer default.

Modifiers CMS verified May 2026

RT / LT — required for laterality

Append RT (right eye) or LT (left eye) to BOTH the J0178 drug line and the 67028 admin line. Without laterality, payer systems can't reconcile bilateral claims and will deny one or both lines.

JZ — required when no drug discarded

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. The 2 mg/0.05 mL vial and PFS are sized to the dose, so wastage is typically zero. JZ applies to nearly every reference Eylea claim. Per Retina Today: "Retina drugs are frequently reported with modifier -JZ."

JW — rarely applies

Use JW only if ≥1 billable unit (1 mg) was actually wasted. Because the vial / PFS is sized to the dose, this is uncommon for adult dosing. JW is more relevant for pediatric ROP (0.4 mg dose) where part of the single-dose container is discarded. If you bill JW, the wasted units are reported on a separate line from the administered units, with documentation in the medical record.

Modifier 25 — same-day E/M

Append modifier 25 to the E/M code when a significant, separately identifiable E/M service is performed on the same day as the injection. Routine pre-injection workup is bundled. New clinical concerns or treatment-decision visits qualify; routine "see how the eye looks before the shot" does not.

NCCI bundling — OCT, fundus photo, and 67028 NCCI verified May 2026

Ophthalmology-specific bundling that drives a large share of retina claim denials.

CMS National Correct Coding Initiative (NCCI) bundles several diagnostic services with 67028 when performed same-day:

Eye visit codes (92012, 92014) are NOT bundled with 67028, so they're often the better choice for the visit portion of an injection encounter.

ICD-10-CM diagnosis codes FY2026 verified May 2026

Use the most specific code supported by the encounter documentation.

Site of care & place of service Verified May 2026

Eylea is administered in-office or in an ASC. Home administration does not apply for intravitreal injections. ROP injections occur in the NICU/hospital outpatient setting.

Intravitreal injections must be performed by an ophthalmologist or qualified retina specialist in a setting with sterile injection capability. Home administration is not a valid pathway for Eylea, so home-infusion HCPCS codes (S9329, S9379, 99601, G0089) do not apply. The legitimate sites of care for adult retina indications are physician office, ophthalmology-based ASC, and hospital outpatient. ROP injections in neonates typically occur in a NICU or hospital outpatient setting under appropriate sedation/topical anesthesia.

Payer site-of-care steering

Both UnitedHealthcare and Aetna apply site-of-care utilization management to ophthalmology anti-VEGF injections, generally favoring office (POS 11) and ophth ASC (POS 24) over hospital outpatient (POS 19/22) due to higher facility fees. If your practice operates under a hospital's billing TIN, expect a payer challenge for hospital outpatient billing.

Claim form field mapping Regeneron 2025 + Retina Today

CMS-1500 / 837P (physician office, ASC; POS 11/24).

Source: Retina Today — How to Create Clean Claims; Regeneron J-Code Billing & Coding Brochure.

Payer policy snapshot Reviewed May 2026

Bevacizumab step + biosimilar preference are the dominant utilization-management levers for reference Eylea.

What to document for reference Eylea approval (when biosimilar is preferred)

• Bevacizumab trial: date(s), ≥3 doses, OCT/VA pre-post showing minimal response — OR documented contraindication / intolerance
• Biosimilar trial / contraindication: which biosimilar(s) were tried and why they failed (documented response data, intolerance, supply-chain issues)
• ROP-specific: P07.x preterm birth code + H35.1x ROP stage + clinical justification for anti-VEGF over alternative ROP therapy
• Specific clinical reason reference Eylea is required vs. a covered alternative

Why this differs from the Eylea HD pathway

Eylea HD (J0177) has no biosimilars, so step therapy is bevacizumab-only. Reference Eylea (J0178) now has biosimilar competition, so step therapy is bevacizumab plus biosimilar preference. The practical implication: a payer-approved aflibercept regimen in 2026 is increasingly likely to be a biosimilar Q-code (especially Pavblu Q5147) rather than reference J0178.

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.

Coverage

No NCD or LCD specific to reference Eylea. The relevant MAC billing & coding article is A52451 ("Billing and Coding: Ranibizumab and biosimilars, Aflibercept, Aflibercept HD, Brolucizumab-dbll, Faricimab-svoa..."). All MACs cover J0178 for FDA-approved on-label indications. Bill with a specific H35.32xx, E1x.34x/E1x.35x, H34.81xx, or H35.1x ICD-10.

ASP reimbursement of biosimilars (relevant for cost comparison)

Each aflibercept biosimilar is reimbursed at its own biosimilar ASP + 6% of the reference product's ASP for the first 5 years post-launch (under the "ASP + 6% of reference" rule). This means a biosimilar's per-mg Medicare payment rate is typically lower than reference J0178 only after the biosimilar's own ASP drops below reference. Pavblu (Q5147) Q2 2026 ASP+6% sits at $821.396/mg — currently higher than reference Eylea's $731.885/mg, reflecting the early-launch ASP add-on. Cost differences shift quarterly; pull the live ASP file before quoting.

Code history

• J0178 — permanent code for "Injection, aflibercept, 1 mg" — in effect since the original Eylea launch (post-2011 BLA approval).
• Biosimilar Q-codes effective dates (CMS HCPCS quarterly updates): Pavblu Q5147 (4/1/2025), Ahzantive Q5150 (4/1/2025), Enzeevu Q5149 (4/1/2025), Opuviz Q5153 (7/1/2025), Yesafili Q5155 (9/30/2025), Eydenzelt (TBD).

Canonical code source: CMS HCPCS quarterly update file.

Patient assistance — EYLEA4U Regeneron verified May 2026

• EYLEA4U Patient Support Program: 1-855-EYLEA4U / 1-855-395-3248, M–F 9 a.m.–8 p.m. ET. Shared program covers both reference Eylea and Eylea HD.
• Commercial Copay Card: as low as $0 copay per Eylea treatment for eligible commercially-insured patients (excluded for Medicare, Medicaid, federal program patients per federal anti-kickback statute)
• Patient Assistance Program (PAP): free drug for uninsured / underinsured patients meeting income requirements
• Independent foundations: support for Medicare patients via foundations like Patient Access Network (PAN) and HealthWell — verify open funds quarterly
• Provider portal: eyleahcp.com for benefits investigation submission

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Eylea?

Eylea (aflibercept 2 mg) is billed under HCPCS J0178 — "Injection, aflibercept, 1 mg." Each milligram equals one billable unit, so the standard 2 mg intravitreal dose is billed as 2 units. The high-dose 8 mg formulation, Eylea HD, uses a separate code: J0177. Aflibercept biosimilars each carry their own Q-code (Yesafili Q5155, Opuviz Q5153, Pavblu Q5147, Ahzantive Q5150, Enzeevu Q5149).

How many units do I bill for an Eylea dose?

Bill 2 units of J0178 per Eylea injection. The drug comes as 2 mg / 0.05 mL in a single-dose vial or prefilled syringe; 1 mg = 1 unit; 2 mg = 2 units. A common biller error is billing 8 units of J0178 for an Eylea HD dose — that denies because both the J-code (should be J0177) and the units are wrong.

What is the administration code for Eylea?

CPT 67028 — "Intravitreal injection of a pharmacologic agent (separate procedure)." Bill 67028 with an RT (right eye) or LT (left eye) modifier. For bilateral same-day injections, most payers require two separate line items with RT and LT, full fee on each — not modifier 50. The administration code must be billed on the same claim as the drug.

How many biosimilars are approved for Eylea?

Six aflibercept biosimilars referencing Eylea 2 mg are FDA-approved as of May 2026: Yesafili (aflibercept-jbvf, Q5155), Opuviz (aflibercept-yszy, Q5153), Pavblu (aflibercept-ayyh, Q5147), Ahzantive (aflibercept-mrbb, Q5150), Enzeevu (aflibercept-abzv, Q5149), and Eydenzelt (aflibercept-boav, October 2025 — no permanent code yet, bill C9399 or J3590). Yesafili and Opuviz are the only two designated as interchangeable, meaning a pharmacist may substitute them without prescriber approval where state law permits. None are biosimilars of Eylea HD (J0177).

Does Eylea require step therapy?

Yes, at most major payers — and increasingly reference Eylea itself is non-preferred relative to biosimilars. UnitedHealthcare's anti-VEGF policy requires a documented bevacizumab trial first, then directs eligible patients to aflibercept-2 mg biosimilars (Pavblu, Yesafili, Opuviz) before reference Eylea. Aetna's Medicare Part B program classifies reference Eylea as non-preferred (favoring bevacizumab and biosimilars). Many BCBS plans now prefer Pavblu over reference Eylea. Verify each payer.

What are the FDA-approved indications for Eylea?

Five indications: neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (CRVO and BRVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). The ROP indication (pediatric, 0.4 mg dose) is unique to Eylea 2 mg and is NOT shared with Eylea HD or any of the approved biosimilars.

What is the Medicare reimbursement for J0178?

Medicare Part B reimburses J0178 at ASP + 6%. Q2 2026 ASP+6% was $731.885/mg, putting a 2 mg dose at approximately $1,463.77 before sequestration. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%. ASP is updated quarterly by CMS. Biosimilar Q-codes are reimbursed at biosimilar ASP + 6% of the reference product's ASP for the first 5 years post-launch.

What is the difference between Yesafili/Opuviz interchangeable and the other 4 aflibercept biosimilars?

FDA designated Yesafili (Biocon, Q5155) and Opuviz (Samsung Bioepis/Biogen, Q5153) as interchangeable on May 20, 2024. Interchangeable means a pharmacist can substitute the biosimilar for reference Eylea without prescriber approval, subject to state law. Pavblu (Amgen Q5147), Ahzantive (Formycon Q5150), Enzeevu (Sandoz Q5149), and Eydenzelt (Celltrion, no code yet) are biosimilars but NOT interchangeable — substitution requires prescriber approval. From a coding standpoint, every biosimilar still uses its own Q-code on the claim regardless of interchangeability designation.

Are 67028 and OCT (92133/92134) bundled by NCCI?

Yes. NCCI bundles 67028 with 92133/92134 (OCT scans) and 92250 (fundus photography) when performed same-day. To unbundle, append modifier XU or 59 to the bundled code with documented separate medical necessity (e.g., the OCT informed a treatment decision distinct from the injection itself). Without proper documentation and modifier, the bundled service will deny.

Source documents

1. DailyMed — EYLEA (aflibercept 2 mg) Prescribing Information
   FDA-approved label (BLA 125387), setid f96cfd69-da34-41ee-90a9-610a4655cd1c
2. Regeneron — Full Prescribing Information (PDF)
   Manufacturer-hosted PI for reference Eylea 2 mg
3. EYLEA4U HCP portal
   Benefits investigation, copay card, PAP enrollment (shared with Eylea HD)
4. AAO — New HCPCS codes for aflibercept biosimilars
   Q-code rollout for Pavblu, Ahzantive, Enzeevu, Opuviz, Yesafili
5. FDA — first interchangeable Eylea biosimilars (Yesafili, Opuviz)
   May 20, 2024 interchangeability designation
6. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026
7. CMS HCPCS Quarterly Update File
   Source for Q-code effective dates (Q5147, Q5149, Q5150, Q5153, Q5155)
8. CMS MCD Article A52451 — Aflibercept Billing & Coding
   MAC billing/coding article covering aflibercept and related anti-VEGF agents
9. UnitedHealthcare — Ophthalmologic VEGF Inhibitors policy
   Step-therapy criteria; bevacizumab + biosimilar pathway
10. Aetna CPB 0701 — VEGF Inhibitors for Ocular Indications
11. Aetna Medicare Part B Eylea / Eylea HD / Biosimilars criteria (2507-A)
    Reference Eylea non-preferred classification
12. Blue Shield of California — Aflibercept (Eylea/Eylea HD) policy
    Effective April 3, 2024
13. Retina Today — How to Create Clean Claims
    CMS-1500 field-by-field claim guidance for retina
14. Retina Today — The Effect of Bilateral Rules on Retina Coding
    RT/LT vs modifier 50 guidance
15. AAPC — CPT 67028
    Code descriptor and bilateral billing notes
16. CMS NCCI — National Correct Coding Initiative edit tables
    67028 + 92133/92134/92250 bundling edits

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 2, 2026 — Initial publication. ASP data: Q2 2026 (J0178 = $731.885/mg ASP+6%). Biosimilar landscape current to Eydenzelt approval (Oct 9, 2025). Payer policies: UHC Ophth VEGF Inhibitors, Aetna CPB 0701 + MedB 2507-A, Blue Shield CA aflibercept (Apr 3, 2024).

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical policy documents. Biosimilar status (Q-codes, interchangeability, code effective dates) is read from CMS HCPCS quarterly files and FDA Purple Book records. We do not paraphrase from billing-software vendor blogs. When manufacturer guidance and payer policy conflict (as happens with bilateral injection coding, step-therapy rules, and biosimilar substitution), we surface the conflict rather than picking a side.